<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811159</url>
  </required_header>
  <id_info>
    <org_study_id>ZPU-203EXT</org_study_id>
    <nct_id>NCT02811159</nct_id>
  </id_info>
  <brief_title>An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</brief_title>
  <official_title>An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <brief_summary>
    <textblock>
      To determine the safety of extended treatment with Proellex in women who have successfully
      completed either study ZPV-201 or ZPU-203 and meet eligibility criteria.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects who become amenorrheic over the course of the study</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in UFS-QOL Symptom Severity score comparing to the previous study baseline and study baseline</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the individual UFS-QOL sub scores</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PBAC scores</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change from parent study baseline and study baseline in total uterine fibroid volume measured by MRI</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Proellex 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telapristone acetate, 1 oral capsule, once a day, for three 18-week courses separated by an Off Drug Interval (ODI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex 12 mg</intervention_name>
    <arm_group_label>Proellex 12 mg</arm_group_label>
    <other_name>Telapristone Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed either study ZPV-201 or ZPU-203

          -  Agreement not to attempt to become pregnant during the trial

          -  Agreement to use alcohol in moderation and record the daily consumption (note:
             elevated liver enzymes may result in discontinuation from the study)

          -  Ability to complete a daily subject diary and study procedures in compliance with the
             protocol

          -  Women of child-bearing potential must be willing to use double-barrier contraception
             during the study and off-drug intervals. Acceptable double-barrier methods are: male
             condom with spermicide; male condom with diaphragm; diaphragm containing spermicide
             plus additional intra-vaginal spermicide

          -  Has a negative pregnancy test at Visit 1

          -  Subject is available for all treatment and follow-up visits

        Exclusion Criteria:

          -  Subject had a significant decrease in bone mineral density while participating in
             ZPV-201 or ZPU-203 (total hip or spine measurement decreased by 5% or more)

          -  Subject has undergone hysterectomy and/or bilateral oophorectomy since enrollment in
             ZPV-201 or ZPU-203.

          -  Subject is pregnant or lactating or is attempting or expecting to become pregnant
             during the entire study period

          -  Subjects with abnormally high liver enzymes or liver disease. (ALT or AST exceeding 2
             x ULN AND total bilirubin exceeding 1.5 x ULN at Visit 1 and confirmed on repeat).

          -  Subject has a hemoglobin of &lt;7.5 g/dL at Visit 1

          -  Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids,
             DHEA or hormonal products for at least 2 weeks prior to Visit 1

          -  Use of oral contraceptives in the 30 days preceding screening. Use of Depo-Provera® in
             the preceding 10 months.

          -  Use of GnRHas (e.g. Lupron Depot) within 3 months prior to screening (Lupron Depot
             must have a wash-out period of 3 months prior to screening)

          -  Has an IUD in place

          -  Current cervical dysplasia classified as Atypical Squamous Cells of Undetermined
             Significance (ASCUS) associated with high-risk human papilloma virus (HPV)

          -  Current diagnosis of Low/High Grade Squamous Intraepithelial Lesion (LGSIL or HGSIL),
             endometrial polyps or hyperplasia

          -  Observation or history of abnormal endometrial biopsy including the presence of EIN

          -  Recent history (within past 6 months) of alcoholism or drug abuse

          -  Endometrial stripe ≥18 mm in thickness at Visit 1 (subject may be enrolled with
             sponsor approval)

          -  Subject is currently taking cimetidine or spironolactone or has taken them in the last
             30 days

          -  Clinically significant abnormal findings on Visit 1 examination and laboratory
             assessments or any condition which in the opinion of the investigator would interfere
             with the participant's ability to comply with the study instructions or endanger the
             participant if she took part in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

